Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: lumiliximab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 94 | 0.91 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6927
Sealed predictions
- FCER2 in dopamine neurons, braak+0.11 (p 0.785) → -0.58 (p 0.102)receipt 6934
Swarm cases
receipt 6934: FCER2 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.332, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.23 (p 0.355, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.32 (p 0.191, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.15, sign flips 0; without severely affected donors -0.24 (p 0.332, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FCER2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts